Vericel Corporation
http://vcel.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vericel Corporation
Erasca Revamps With Two In-Licensings, $160m Private Placement
The San Diego biotech is also de-emphasizing three ongoing targeted cancer therapy candidates and giving itself the flexibility to focus on RAS- or KRAS-targeting approaches.
Relyvrio’s Failure Sparks NeuroSense ALS Development Changes
NeuroSense plans to adjust its upcoming clinical trial to avoid the fate of Amylyx’s ALS candidate, which was recently withdrawn from the market due to a lack of efficacy.
FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why
Rahul Rao, the deputy director of the FTC Bureau of Competition, discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.
AstraZeneca Confident Of Cementing Lead In Respiratory
The UK major’s head of respiratory and immunology, Pablo Panella, tells Scrip that AstraZeneca’s well established presence in the field “gives us an edge.”
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Aastrom Biosciences, Inc.
- Genzyme Biosurgery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice